#1leading
KIT D816V is necessary and sufficient as the sole driver of indolent SM, while advanced SM requires cooperating mutations in a multi-hit model
30 studies·pathogenesis
75
evidence
Systemic Mastocytosis
Also known asSMSystemic Mast Cell Disease
Systemic mastocytosis is a clonal hematologic neoplasm characterized by abnormal proliferation and accumulation of neoplastic mast cells in one or more extracutaneous organs, primarily the bone marrow. Driven by activating KIT mutations — most commonly KIT D816V, found in >90% of adult cases — SM spans a clinical spectrum from indolent disease (ISM, ~75% of cases) with near-normal life expectancy to aggressive variants (ASM, SM-AHN, MCL) with poor prognosis.
Data sourced from 32 published studies with evidence grading (A–D). Last reviewed . Not medical advice.
Pathophysiology✓Well understood
Treatment✓Effective options available
Genetic basis✓Well characterized
Research activity
32 studies·3 active trials·2001–2025
Epidemiology
- Total cases
- Unknown
- Mean onset
- 55 years
- Onset range
- 18–80 years
- Sex ratio (M:F)
- 1:1
- Diagnostic delay
- ~5 years
- Discovered
- 1869 (Nettleship and Tay (cutaneous); Ellis (systemic, 1949))
- Prevalence
- 10-24 per 100,000
- Classification
- Hematologic, Mast cell neoplasm
Cardinal Features
12 key symptoms and signs
| Feature | Frequency | Category | Sources |
|---|---|---|---|
Urticaria pigmentosa / maculopapular cutaneous mastocytosis Red-brown macules and papules that urticate on rubbing (positive Darier sign). Present in most ISM patients. Adult-onset urticaria pigmentosa is highly suggestive of systemic disease. | 80% | dermatologic | |
Flushing Episodic vasodilation causing redness of face, neck, and upper trunk. Triggered by mast cell mediator release (histamine, prostaglandins). Common triggers include heat, exercise, alcohol, and Hymenoptera stings. | 60% | vascular | |
Pruritus Generalized itching caused by histamine release from mast cells. Can be severe and significantly impact quality of life. Responds to H1 antihistamines. | 55% | dermatologic | |
Anaphylaxis Severe systemic mast cell degranulation causing hypotension, syncope, and potentially death. Hymenoptera venom is the most common trigger. Risk 7.2x higher than general population. All SM patients should carry epinephrine autoinjectors. | 49% | immunologic | |
Abdominal pain The most common GI symptom. Caused by mast cell mediator release and gastric acid hypersecretion. May be crampy or diffuse. | 51% | gastrointestinal | |
Diarrhea Affects 30-50% of patients. Due to gastric acid hypersecretion, malabsorption from mucosal edema, and altered bowel motility caused by mast cell mediators. | 43% | gastrointestinal | |
Fatigue One of the most common and debilitating symptoms, affecting up to 70-90% of patients. Chronic and often underappreciated. Significantly impacts quality of life. | 80% | constitutional | |
Bone pain Musculoskeletal pain particularly affecting the long bones and spine. Associated with osteoporosis and osteolytic/osteosclerotic bone lesions caused by mast cell mediator effects on bone remodeling. | 40% | musculoskeletal | |
Elevated serum tryptase (>20 ng/mL) Basal serum tryptase >20 ng/mL is a minor WHO diagnostic criterion for SM. Correlates with mast cell burden (r=0.8). Median level 67 ng/mL in SM. Must be interpreted in context of hereditary alpha-tryptasemia. | 90% | laboratory | |
Hepatosplenomegaly Liver and/or spleen enlargement due to mast cell infiltration. More common in advanced subtypes. Splenomegaly is a B-finding; organ dysfunction with ascites or portal hypertension is a C-finding. | 30% | organomegaly | |
Cognitive dysfunction / brain fog Neurocognitive symptoms including difficulty concentrating, memory impairment, and mental clouding. Increasingly recognized as a significant contributor to reduced quality of life. | 35% | neurologic | |
Hypotension / presyncope Episodic drops in blood pressure caused by histamine-mediated vasodilation and increased vascular permeability during mast cell degranulation. Can progress to anaphylactic shock. | 25% | cardiovascular |
Hypothesis Tracker
Competing explanations ranked by evidence weight
#2leading
The STAT5-PI3K-AKT-mTOR axis is the dominant oncogenic signaling cascade downstream of KIT D816V and the primary target for therapeutic intervention
20 studies·pathogenesis
70
evidence
#3emerging
Deep molecular responses (KIT D816V undetectable) achieved by selective KIT inhibitors can alter the natural history of SM and prevent progression
8 studies·treatment
50
evidence
#4emerging
Hereditary alpha-tryptasemia (HαT) modifies SM phenotype, increasing mediator symptoms and anaphylaxis risk independent of mast cell burden
6 studies·genetics
40
evidence
Open Questions
Can selective KIT D816V inhibitors prevent progression from indolent to advanced SM?
Avapritinib achieves deep molecular responses in ISM, but whether sustained KIT D816V suppression prevents clonal evolution and disease progression is unknown. Long-term PIONEER follow-up may provide initial answers.
What determines why some patients with KIT D816V develop ISM while others progress to advanced SM?
Nearly all SM subtypes share KIT D816V, yet clinical outcomes range from near-normal survival (ISM) to median 2 months (MCL). The multi-hit model explains some but not all variance.
How can anaphylaxis risk be better predicted and stratified in individual SM patients?
Nearly half of ISM patients experience anaphylaxis, but current risk factors (Hymenoptera sensitization, absence of skin lesions, male sex) have limited predictive power for individual patients.
Can combination therapies targeting KIT D816V plus downstream pathways improve outcomes in multi-mutated advanced SM?
Patients with >=2 S/A/R mutations have median OS of only 2.7 years. Single-agent KIT inhibitors may not overcome the survival advantage conferred by additional oncogenic mutations.
What is the role of the bone marrow microenvironment in supporting neoplastic mast cell survival?
Neoplastic mast cells form dense aggregates in bone marrow, often with associated fibrosis and angiogenesis. The microenvironmental signals sustaining these niches are poorly characterized.
Recent Updates
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
In May 2023, avapritinib became the first and only FDA-approved targeted therapy for ISM, based on PIONEER trial data showing significant symptom reduction and mast cell burden decrease vs placebo. This marks a paradigm shift from purely symptomatic management to targeted disease modification in non-advanced SM.
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
Longer-term follow-up of PIONEER trial patients demonstrates that avapritinib maintains its favorable benefit-risk profile after 3+ years of therapy, with continued symptom improvement and mast cell burden reduction. Supports avapritinib as chronic treatment for ISM.
WHO 2022 and ICC 2022 classification updates published
Updated diagnostic criteria add CD30 as a minor criterion, recognize BMM as a distinct subtype, account for hereditary alpha-tryptasemia, and incorporate KIT D816V VAF >=10% as a B-finding. These refine risk stratification and diagnosis.
Swedish and Danish population-based studies reveal higher SM prevalence than expected
Two large Scandinavian population-based studies found SM prevalence of 11-24 per 100,000 — considerably higher than previously thought. Increasing incidence attributed to improved diagnostics and disease awareness rather than true increase in disease occurrence.
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
Pooled data from EXPLORER and PATHFINDER trials show avapritinib achieves deep molecular responses in advanced SM, with KIT D816V becoming undetectable in bone marrow of 30% of patients — a new response benchmark previously unattainable with midostaurin.
Midostaurin FDA-approved for advanced systemic mastocytosis
In April 2017, midostaurin became the first FDA-approved targeted therapy for advanced SM (ASM, SM-AHN, and MCL) based on a phase II open-label trial showing overall response rate of 60% including 45% major responses. This represented the first targeted option beyond cytoreductive chemotherapy for advanced SM subtypes.
Highly sensitive KIT D816V digital PCR enables peripheral blood screening
Jara-Acevedo et al. (2015) validated a highly sensitive digital droplet PCR assay detecting KIT D816V at allele frequencies as low as 0.01% in peripheral blood. This enables non-invasive screening for SM without bone marrow biopsy and facilitates longitudinal molecular monitoring of treatment response.
Multi-lineage KIT D816V clonality mapped in SM with associated hematological neoplasms
Sotlar et al. demonstrated that KIT D816V is present across multiple hematopoietic lineages (mast cells, monocytes, eosinophils) in SM-AHN, proving SM is a clonal stem cell disorder rather than a mast cell-restricted disease. This finding has implications for treatment, as stem cell-targeting therapies may be needed for deep remission.
Avapritinib approved by EMA for advanced SM based on PATHFINDER trial
The EMA granted marketing authorization for avapritinib in advanced SM in June 2022, based on the PATHFINDER trial showing an overall response rate of 75% and complete remission in 36% of patients. Avapritinib demonstrated superiority over midostaurin with deeper molecular responses and better tolerability.
Hereditary alpha-tryptasemia identified as common SM confounder
Lyons et al. (2016) identified hereditary alpha-tryptasemia (HaT), caused by increased TPSAB1 copy number, in 5-6% of the general population. HaT elevates baseline tryptase independent of mast cell burden, complicating SM diagnosis. Updated WHO/ICC criteria now account for HaT when interpreting elevated tryptase in suspected SM cases.